GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies

We read with interest the recent letter by Ramiro et al 1 reporting data from a systematic literature review on the measurement of enthesitis, dactylitis and nail disease in psoriatic arthritis (PsA) clinical trials. The authors highlight the great variety in the outcome measures chosen, cut points...

Descripció completa

Dades bibliogràfiques
Autors principals:	Tillett, W, Orbai, A, Ogdie, A, Leung, Y, Strand, V, Gladman, D, Mease, P, Coates, L
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2017

Ítems similars

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
per: Leung, Y-Y, et al.
Publicat: (2023)

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative
per: Antony, A, et al.
Publicat: (2021)

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 annual meeting: report and plan for completing the core outcome measurement set
per: Leung, Y, et al.
Publicat: (2019)

The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates
per: Leung, YY, et al.
Publicat: (2020)

Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients
per: Orbai, A-M, et al.
Publicat: (2019)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
per: Holland, R, et al.
Publicat: (2018)

Classification and outcome measures for psoriatic arthritis
per: Leung, Y, et al.
Publicat: (2018)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
per: Tillett, W, et al.
Publicat: (2020)

OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF
per: Leung, Y-Y, et al.
Publicat: (2021)

Endorsement of the 66/68 joint count for the measurement of musculoskeletal disease activity: OMERACT 2018 psoriatic arthritis workshop report
per: Duarte-García, A, et al.
Publicat: (2019)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
per: Coates, L, et al.
Publicat: (2017)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
per: Soriano, ER, et al.
Publicat: (2023)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
per: Leung, YY, et al.
Publicat: (2020)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
per: Coates, LC, et al.
Publicat: (2022)

PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials
per: Orbai, A, et al.
Publicat: (2018)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
per: Gladman, DD, et al.
Publicat: (2018)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences
per: Coates, L, et al.
Publicat: (2022)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
per: Leung, Y-Y, et al.
Publicat: (2020)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
per: Leung, YY, et al.
Publicat: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2023)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
per: Coates, L, et al.
Publicat: (2016)

GRAPPA 2018 project report
per: Goel, N, et al.
Publicat: (2019)

GRAPPA 2017 Project Report
per: Callis Duffin, K, et al.
Publicat: (2018)

Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative
per: De Marco, G, et al.
Publicat: (2020)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
per: Alexis Ogdie, et al.
Publicat: (2023-05-01)

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
per: Poddubnyy, D, et al.
Publicat: (2021)

GRAPPA 2019 project report
per: Goel, N, et al.
Publicat: (2020)

Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
per: Denis Poddubnyy, et al.
Publicat: (2021-12-01)

Psoriatic arthritis: prospects for the future
per: Hackett, S, et al.
Publicat: (2022)

GRAPPA 2016 Project Report
per: Helliwell, P, et al.
Publicat: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
per: Helliwell, PS, et al.
Publicat: (2022)

A presença da reumatologia brasileira no GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) The presence of the Brazilian rheumatology in the GRAPPA
per: Cláudia Goldenstein-Schainberg, et al.
Publicat: (2011-10-01)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
per: Coates, L, et al.
Publicat: (2019)

Proceedings of the GRAPPA 2022 executive retreat
per: Ng, B, et al.
Publicat: (2023)

Management of dactylitis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations
per: Palominos, PE, et al.
Publicat: (2022)

Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project
per: Philip J Mease, et al.
Publicat: (2024-02-01)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
per: Orbai, A-M, et al.
Publicat: (2019)

Psoriatic arthritis: prospects for the future
per: Simon Hackett, et al.
Publicat: (2022-03-01)